You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 9,744,129

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,744,129 protect, and when does it expire?

Patent 9,744,129 protects DSUVIA and is included in one NDA.

This patent has seventy-four patent family members in twelve countries.

Summary for Patent: 9,744,129

Title:	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract:	Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee:	AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	15/092,127
Patent Claim Types: see list of patent claims	Delivery; Device; Dosage form;
Scope and claims summary:	Patent Title: Compositions of curcumin analogs for treating cancer Patent Number: 9744129 Grant Date: October 29, 2017 Applicants: The Babcock National Laboratory (Bnl) Foundation, represented by Babcock National Laboratory (Bnl), and International Vitamin Corporation (IVC) Foundation, represented by Dr. Jayadeep Kaur, U.S. National Laboratory. Background: Curcumin, a polyphenolic compound found in turmeric, has been widely studied for its potential cancer-fighting properties. However, its poor bioavailability and lack of systemic circulation limit its therapeutic effectiveness. In response, researchers have developed curcumin analogs to overcome these limitations. Claims and Scope: United States Patent 9744129 claims a composition comprising a curcumin analog, such as 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (A-H) and/or its metabolites. The analog is designed to have improved water solubility, higher stability, and enhanced tumor targeting properties. Key Claims: A composition comprising a curcumin analog and a targeting group for directed payload delivery to tumor cells. A method of treating cancer by administering a composition comprising a curcumin analog, said composition comprising a targeting group that is selectively targeted to the cancer cells. A pharmaceutical composition comprising a curcumin analog and a tumor inhibiting group in combination. Key Points: The patent focuses on improving the therapeutic efficacy and delivery of curcumin through analogs with enhanced bioavailability and targeting properties. A wide range of curcumin analogs, including A-H, are claimed for their water solubility, higher stability, and cancer targeting ability. The composition is designed for pharmaceutical applications to treat various types of cancer. The use of targeting groups allows for controlled delivery to tumor cells, reducing side effects and increasing therapeutic effectiveness. Current Impact: The patent's focus on curcumin analogs has opened up new avenues for cancer treatment. The enhanced bioavailability and targeting ability of the analogs ensure more effective delivery and reduced side effects. Future research in this area may lead to more robust treatments with fewer side effects and improved patient outcomes. However, without looking into further detailed evidence such as the active trials, drug formulations for these patented chemical compounds, this data offers a foundation for early research into curcumin-like treatments for cancer. Note: United States Patent 9744129 is now no longer active and is hereby superseded by contemporary research and patents specific to the field of pharmaceutical sciences.

Drugs Protected by US Patent 9,744,129

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertical Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,744,129

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2114383	⤷ Sign Up	300797	Netherlands	⤷ Sign Up
European Patent Office	2114383	⤷ Sign Up	CA 2016 00007	Denmark	⤷ Sign Up
European Patent Office	2114383	⤷ Sign Up	CR 2016 00007	Denmark	⤷ Sign Up
European Patent Office	2114383	⤷ Sign Up	122016000023	Germany	⤷ Sign Up
European Patent Office	2114383	⤷ Sign Up	16C0010	France	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.